Sunrise, FL – February 9, 2016 – US STEM CELL, Inc. (OTCQB:USRM) – The chairman of the board of directors of US Stem Cell Inc, Dr. William P. Murphy, Jr., delivered the keynote address at the 2nd annual Academy of Regenerative Practices (www.regenerativeacademy.com) in Ft. Lauderdale, Florida this past weekend. A medical pioneer and founder of Cordis Corporation (now a Johnson & Johnson company), Dr Murphy is a medical doctor and inventor of medical devices including collaborating on a flexible sealed blood bag used for blood transfusions as well as patents for inventing the physiologic pace maker and the artificial kidney. He is the son of the American physician William Parry Murphy who shared the Nobel Prize in Physiology for Medicine in 1934, and Harriett Adams, the first licensed female dentist in Massachusetts.
During the many presentations on technological advancements and clinical achievements in stem cell therapeutics and regenerative medicine at the ARP Conference, Dr. Murphy’s presentation highlighted the challenges of bringing new technologies to patients and the importance of staying dedicated to the stem cell field as it holds great promise for millions of patients. Dr Murphy highlighted that at US Stem Cell, this is a reality today as over 4000 patients have been treated using regenerative medicine therapies and technology. “Bringing new technologies to the bedside to help patients in need is never void of great challenges. I commend the leaders of the fields of regenerative medicine and stem cell therapies and urge you to continue on this effort. It is now evident that stem cell therapies hold the potential of being the penicillin of our generation”, stated Dr Murphy.
A recap of the 2016 Academy of Regenerative Practices is provided at:https://www.facebook.com/regenerativeacademy/
About U.S.Stem Cell, Inc.
US Stemcell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.
Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.
About the Academy of Regenerative Practices
The Academy of Regenerative Practices is a network of physicians and scientists dedicated to the health and well-being of patients through the use of regenerative therapies. We are committed to bringing cutting edge stem cell and regenerative technology to clinical practices. Our goal is to educate medical providers on the most current cellular techniques and indications so that patients may benefit from a more natural and less invasive process.
The ARP is dedicated to the education of medical practitioners in the latest cellular medicine techniques and therapies. The ARP provides a forum for multiple disciplines to integrate and learn the most advanced regenerative clinical applications.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forwardlooking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q.